Cancer vaccines targeting HER2/neu for early breast cancer

Woo Sang Ryu, Gil Soo Son

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Recent studies of immune responses to pathogens have identified pathogen-associated molecular patterns recognized by the innate immune system through specialized receptors called toll-like receptors (TLRs). Signaling through these receptors initiates robust immune responses. By exploiting TLR signaling pathways, immunity to tumor-associated antigens may be generated. Many tumor-associated antigens are involved in the regulation of tumor phenotype or carcinogenesis. Immune targeting of these antigens may either alter the tumor phenotype, yielding a more treatable tumor, or eradicate early tumor stem cells preventing tumor formation. The oncoprotein HER2/neu, which is often overexpressed in ductal carcinoma in situ (DCIS), may provide such a target. Immune responses directed against HER2/neu may eliminate the disease, make tumors more amenable to anti-estrogen therapy, or prevent escape of hormone resistant tumor phenotypes. Effective breast cancer prevention in preclinical studies utilizing murine HER2/neu transgenic models has stimulated interest in, and optimism regarding, protective breast cancer vaccines in humans. Induction of anti-HER2/neu T cell (CD4+ and CD8+) and B cell responses has been demonstrated in an ongoing clinical study targeting HER2/neu using a TLR agonist-primed dendritic cell vaccine. Moreover, these vaccinations lead to reductions in both HER2/neu expression and extent of DCIS. HER2/neu expression and aromatase activity have recently been linked through the intermediary cyclooxygenase 2 (COX-2). This convergence between growth factor and hormone mediated pathwaysprovides additional support for the notion that a significant number of breast cancers may be prevented through effective immune targeting of HER2/neu. As progress is made towards the development of vaccines for breast cancer prevention, the contributions of immune-mediated effecter and inhibitory mechanisms to the pathogenesis of HER2/neu overexpressing breast cancer will need to be better understood.

Original languageEnglish
Pages (from-to)5-13
Number of pages9
JournalJournal of Breast Cancer
Volume13
Issue number1
DOIs
Publication statusPublished - 2010 Mar 1

Fingerprint

Cancer Vaccines
Breast Neoplasms
Toll-Like Receptors
Neoplasms
Carcinoma, Intraductal, Noninfiltrating
Neoplasm Antigens
Phenotype
Vaccines
Aromatase
Neoplastic Stem Cells
Oncogene Proteins
Cyclooxygenase 2
Dendritic Cells
Growth Hormone
Immune System
Immunity
Intercellular Signaling Peptides and Proteins
Estrogens
Carcinogenesis
Vaccination

Keywords

  • Breast neoplasms
  • Dendritic cells
  • Her2/neu
  • Vaccines

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Cancer vaccines targeting HER2/neu for early breast cancer. / Ryu, Woo Sang; Son, Gil Soo.

In: Journal of Breast Cancer, Vol. 13, No. 1, 01.03.2010, p. 5-13.

Research output: Contribution to journalArticle

@article{f86adcb39940409f928c323c7e9c5f77,
title = "Cancer vaccines targeting HER2/neu for early breast cancer",
abstract = "Recent studies of immune responses to pathogens have identified pathogen-associated molecular patterns recognized by the innate immune system through specialized receptors called toll-like receptors (TLRs). Signaling through these receptors initiates robust immune responses. By exploiting TLR signaling pathways, immunity to tumor-associated antigens may be generated. Many tumor-associated antigens are involved in the regulation of tumor phenotype or carcinogenesis. Immune targeting of these antigens may either alter the tumor phenotype, yielding a more treatable tumor, or eradicate early tumor stem cells preventing tumor formation. The oncoprotein HER2/neu, which is often overexpressed in ductal carcinoma in situ (DCIS), may provide such a target. Immune responses directed against HER2/neu may eliminate the disease, make tumors more amenable to anti-estrogen therapy, or prevent escape of hormone resistant tumor phenotypes. Effective breast cancer prevention in preclinical studies utilizing murine HER2/neu transgenic models has stimulated interest in, and optimism regarding, protective breast cancer vaccines in humans. Induction of anti-HER2/neu T cell (CD4+ and CD8+) and B cell responses has been demonstrated in an ongoing clinical study targeting HER2/neu using a TLR agonist-primed dendritic cell vaccine. Moreover, these vaccinations lead to reductions in both HER2/neu expression and extent of DCIS. HER2/neu expression and aromatase activity have recently been linked through the intermediary cyclooxygenase 2 (COX-2). This convergence between growth factor and hormone mediated pathwaysprovides additional support for the notion that a significant number of breast cancers may be prevented through effective immune targeting of HER2/neu. As progress is made towards the development of vaccines for breast cancer prevention, the contributions of immune-mediated effecter and inhibitory mechanisms to the pathogenesis of HER2/neu overexpressing breast cancer will need to be better understood.",
keywords = "Breast neoplasms, Dendritic cells, Her2/neu, Vaccines",
author = "Ryu, {Woo Sang} and Son, {Gil Soo}",
year = "2010",
month = "3",
day = "1",
doi = "10.4048/jbc.2010.13.1.5",
language = "English",
volume = "13",
pages = "5--13",
journal = "Journal of Breast Cancer",
issn = "1738-6756",
publisher = "Korean Breast Cancer Society",
number = "1",

}

TY - JOUR

T1 - Cancer vaccines targeting HER2/neu for early breast cancer

AU - Ryu, Woo Sang

AU - Son, Gil Soo

PY - 2010/3/1

Y1 - 2010/3/1

N2 - Recent studies of immune responses to pathogens have identified pathogen-associated molecular patterns recognized by the innate immune system through specialized receptors called toll-like receptors (TLRs). Signaling through these receptors initiates robust immune responses. By exploiting TLR signaling pathways, immunity to tumor-associated antigens may be generated. Many tumor-associated antigens are involved in the regulation of tumor phenotype or carcinogenesis. Immune targeting of these antigens may either alter the tumor phenotype, yielding a more treatable tumor, or eradicate early tumor stem cells preventing tumor formation. The oncoprotein HER2/neu, which is often overexpressed in ductal carcinoma in situ (DCIS), may provide such a target. Immune responses directed against HER2/neu may eliminate the disease, make tumors more amenable to anti-estrogen therapy, or prevent escape of hormone resistant tumor phenotypes. Effective breast cancer prevention in preclinical studies utilizing murine HER2/neu transgenic models has stimulated interest in, and optimism regarding, protective breast cancer vaccines in humans. Induction of anti-HER2/neu T cell (CD4+ and CD8+) and B cell responses has been demonstrated in an ongoing clinical study targeting HER2/neu using a TLR agonist-primed dendritic cell vaccine. Moreover, these vaccinations lead to reductions in both HER2/neu expression and extent of DCIS. HER2/neu expression and aromatase activity have recently been linked through the intermediary cyclooxygenase 2 (COX-2). This convergence between growth factor and hormone mediated pathwaysprovides additional support for the notion that a significant number of breast cancers may be prevented through effective immune targeting of HER2/neu. As progress is made towards the development of vaccines for breast cancer prevention, the contributions of immune-mediated effecter and inhibitory mechanisms to the pathogenesis of HER2/neu overexpressing breast cancer will need to be better understood.

AB - Recent studies of immune responses to pathogens have identified pathogen-associated molecular patterns recognized by the innate immune system through specialized receptors called toll-like receptors (TLRs). Signaling through these receptors initiates robust immune responses. By exploiting TLR signaling pathways, immunity to tumor-associated antigens may be generated. Many tumor-associated antigens are involved in the regulation of tumor phenotype or carcinogenesis. Immune targeting of these antigens may either alter the tumor phenotype, yielding a more treatable tumor, or eradicate early tumor stem cells preventing tumor formation. The oncoprotein HER2/neu, which is often overexpressed in ductal carcinoma in situ (DCIS), may provide such a target. Immune responses directed against HER2/neu may eliminate the disease, make tumors more amenable to anti-estrogen therapy, or prevent escape of hormone resistant tumor phenotypes. Effective breast cancer prevention in preclinical studies utilizing murine HER2/neu transgenic models has stimulated interest in, and optimism regarding, protective breast cancer vaccines in humans. Induction of anti-HER2/neu T cell (CD4+ and CD8+) and B cell responses has been demonstrated in an ongoing clinical study targeting HER2/neu using a TLR agonist-primed dendritic cell vaccine. Moreover, these vaccinations lead to reductions in both HER2/neu expression and extent of DCIS. HER2/neu expression and aromatase activity have recently been linked through the intermediary cyclooxygenase 2 (COX-2). This convergence between growth factor and hormone mediated pathwaysprovides additional support for the notion that a significant number of breast cancers may be prevented through effective immune targeting of HER2/neu. As progress is made towards the development of vaccines for breast cancer prevention, the contributions of immune-mediated effecter and inhibitory mechanisms to the pathogenesis of HER2/neu overexpressing breast cancer will need to be better understood.

KW - Breast neoplasms

KW - Dendritic cells

KW - Her2/neu

KW - Vaccines

UR - http://www.scopus.com/inward/record.url?scp=77953214770&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953214770&partnerID=8YFLogxK

U2 - 10.4048/jbc.2010.13.1.5

DO - 10.4048/jbc.2010.13.1.5

M3 - Article

AN - SCOPUS:77953214770

VL - 13

SP - 5

EP - 13

JO - Journal of Breast Cancer

JF - Journal of Breast Cancer

SN - 1738-6756

IS - 1

ER -